
    
      This is a randomised two-arm parallel group phase II study. 140 patients will be recruited
      over a period of 12 months, and will be randomised to receive either eight 3-weekly cycles of
      Epirubicin, Oxaliplatin and Capecitabine (EOX) or six 4-weekly cycles of Docetaxel and
      Oxaliplatin (EITax).
    
  